Q2 2025 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) reported an increase in total revenues for the first half of 2025 to approximately $3.2 million, up from $2.3 million in the first half of 2024, driven by strong seed sales from its subsidiary Casterra.
- The company executed a cost reduction plan, resulting in a significant decrease in operating expenses, with total operating expenses net for the first half of 2025 at approximately $7.7 million compared to $11.1 million in the same period last year.
- Evogene Ltd (EVGN) completed the sale of Lavie Bio's assets and the MicroBoost AI for Ag tech-engine to ICL, generating significant cash flow and enhancing the company's financial position.
- The company is focusing on maximizing the value of its ChemPass AI platform, which has been strengthened by the completion of the GeneRator AI foundation model developed in collaboration with Google Cloud.
- Evogene Ltd (EVGN) successfully raised $4.4 million through its ATM facility, providing a solid financial foundation and operational runway of approximately 18 months.
- Evogene Ltd (EVGN) is undergoing a strategic shift, which includes significant organizational changes and workforce reductions, potentially impacting employee morale and operational stability.
- The company reported a net loss for the first half of 2025 of approximately $7.7 million, although this was a decrease from the $9.8 million loss in the same period last year.
- There is uncertainty regarding the commercialization of Casterra's castor seed inventory, as the company is exploring options to sell seeds directly or grow and sell grain.
- The ongoing geopolitical situation in Israel, including the conflict with Hamas and Hezbollah, poses risks and uncertainties that could affect the company's operations and financial performance.
- Evogene Ltd (EVGN) faces challenges in achieving peak sales and establishing new partnerships, particularly in the pharma and agriculture sectors, which are crucial for future growth.
Welcome to Evogene's second quarter 2025 results conference call. (Operator Instructions) As a reminder, this conference is being recorded August 19, 2025. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events.
This presentation contains forward-looking statements relating to future events, and Evogene Ltd, the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results, and or other matters regarding or affecting us that are considered forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1,995, the PSLRA.
And other securities laws as amended statements that are not statements forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should planned, estimated, intend, and potential, or words of similar meaning. We're using forward-looking statements in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
